| Vol. 11.10 – 17 March, 2022 |
| |
|
|
| Scientists revealed a role of airway basal cells in tracheobronchopathia osteochondroplastica progression by acting as a repository of inflammatory and TGFβ-BMP signals, which contributed to both epithelial metaplasia and mesenchymal osteo-chondrogenesis via extracellular signaling and matrix remodeling. [Nature Communications] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers showed that in COPD patients, protein arginine methyltransferase 7 (PRMT7) expression was elevated in the lung tissue and localized to the macrophages. [Nature Communications] |
|
|
|
| The authors demonstrated that YAP/TAZ activation reprogrammed airway secretory cells, which subsequently lost their cellular identity and acquired squamous alveolar type 1 fate in the lung. [EMBO Journal] |
|
|
|
| Investigators identified a novel circular RNA (circRNA)-ANKRD42 from peripheral blood of patients with idiopathic pulmonary fibrosis, which participated in pulmonary fibrosis through the close communication of mechanical stiffness and biochemical signals. [Molecular Therapy] |
|
|
|
| Researchers suggested that micro-computed tomography (CT) analyzable pluripotent stem cell (PSC)-derived alveolar human lung organoids were a promising in vitro model to predict lung toxicity manifestations, including fibrosis. [Cell Biology and Toxicology] |
|
|
|
| To assess methylation profiles in the main COPD target organ, investigators performed an epigenome-wide association study on bronchoalveolar lavage cells. [American Journal of Respiratory Cell and Molecular Biology] |
|
|
|
| The authors established, from single biopsy specimens, a human adult stem cell-derived organoid model representing the upper respiratory airways and lungs and explored the applicability of this model to study respiratory virus infection. [Frontiers in Cellular and infection Microbiology] |
| |
|
|
| Scientists established lorlatinib intermediate resistant cells from a patient-derived cell model. Glycogen synthase kinase 3 (GSK3) inhibitions significantly suppressed lorlatinib intermediate resistant cell growth. [npj Precision Oncology] |
|
|
|
| The authors presented a method for inducing controlled tumor angiogenesis by engineering the microenvironment that could aid in the development of effective anticancer drugs and cancer immunotherapy. [Advanced Healthcare Materials] |
|
|
|
| Scientists found that cinobufotalin (CB) decreased cisplatin (DDP) resistance, migration and invasion in lung adenocarcinoma and showed that CB induced ENKUR expression by suppressing PI3K/AKT signaling to downregulate c-Jun, a negative transcription factor of ENKUR. [Acta Pharmacologica Sinica] |
|
|
|
| Investigators combined multiple “-omics” methods to assess SWI/SNF composition and aberrations in lung adenocarcinoma (LUAD). Mutations in lung SWI/SNF subunits were highly recurrent in their LUAD cohort, and over 70% of the mutations were predicted to have functional impact. [Clinical Epigenetics] |
|
|
|
| Researchers explored the metabolic reprogramming relevant to lung adenocarcinoma metastasis and decoded the underlying intercellular alterations. [Communications Biology] |
|
|
|
| Investigators demonstrated that AXL was a critical targetable driver of immune suppression in STK11/LKB1 mutant NSCLC. [Cell Reports Medicine] |
|
|
|
|
| The authors review the advancements in transformed SCLC, including clinical and pathological characteristics, and the potential effective treatment after SCLC transformation, aiming to give a better understanding of transformed SCLC and provide support for clinical uses. [Seminars in Cancer Biology] |
|
|
|
| Scientists summarize the roles of distinct immunogenic cell death mechanisms on antitumor immunity and recent advances of ferroptosis-, necroptosis- and pyroptosis-inducing agents, and present perspectives on these cell death mechanisms in immunotherapy of SCLC. [Seminars in Cancer Biology] |
|
|
|
| Investigators outline the basic structure and generation characteristic of chimeric antigen receptor-modified T (CAR-T) cells and summarize the common tumor-associated antigens in clinical trials of CAR-T cell therapy for lung cancer. [Thoracic Cancer] |
|
|
|
|
| Foundation Medicine, Inc. announced it has received approval from the US FDA for FoundationOne®CDx to be used as a companion diagnostic to identify patients with NSCLC. [Foundation Medicine, Inc.] |
|
|
|
| Iovance Biotherapeutics, Inc. announced that the US FDA has allowed an IND to proceed for its first genetically modified TIL therapy, IOV-4001, for the treatment of unresectable or metastatic melanoma and stage III or IV NSCLC. [Iovance Biotherapeutics, Inc.] |
|
|
|
|
| April 23 – 26, 2022 Lisbon, Portugal & Online |
|
|
|
|
|
| Genentech, Inc. – South San Francisco, California, United States |
|
|
|
| Gilead Sciences – Foster City, California, United States |
|
|
|
| Fred Hutchinson Cancer Research Center – Seattle, Washington, United States |
|
|
|
| Berlin Institute of Health – Berlin, Germany |
|
|
|
| Thorax Institute – Nantes, France |
|
|
|
|